leuprolide acetate for depot suspension News

12 3 4 5 6 7 8 9 10 11 12 13...40 41 »

|||||||||| leuprolide acetate for depot suspension / Generic mfg.
Journal: Deep-Learning-Enabled SEM Image Segmentation Coupled with Laser Confocal Raman Microscopy: Elucidating Microstructure and Drug Spatial Distribution in Leuprorelin Acetate Microspheres. (Pubmed Central) - Jun 27, 2026
The findings establish that microstructure dictates release behavior and that all observed structural variations are linked to critical process parameters (CPPs), validating the "process determines structure" hypothesis. The established methodology provides a critical technical framework for the reverse engineering and quality equivalence assessment of generic microspheres, as well as for the quality-by-design-based optimization of innovative drug products, thereby advancing both pharmaceutical development and regulatory science.

|||||||||| Ibrance (palbociclib) / Pfizer
A case of HR-positive, HER2-negative Stage IV breast cancer complicated with cerebral infarction, in which palbociclib was effective and treatment was continued at a collaborating hospital. (Poster Session Venue | Kyoto International Conference Center, 1st Floor Event Hall, New Hall; In-Person) - Jun 26, 2026 - Abstract #JBCS2026JBCS_2372;
She was undergoing DAPT therapy (Effient 3.75 mg, low-dose aspirin 100 mg), but a needle biopsy was performed, revealing only mild subcutaneous hemorrhage at the puncture site...We requested that the prescription of palbociclib 75 mg, letrozole, and leuprorelin be continued, and the patient was discharged home after a four-month hospital stay...[Conclusion] In a case where cerebral infarction accompanied by paralysis symptoms and Stage IV breast cancer coexisted, preparations for breast cancer treatment were carried out in parallel with treatment for acute cerebral infarction. After confirmation of improvement in paralysis symptoms, breast cancer treatment was promptly started, and a cooperative system with other facilities was established during the rehabilitation period, enabling the safe and effective continuation of breast cancer treatment.

|||||||||| leuprolide acetate for depot suspension / Generic mfg.
One case in which endometrial hyperplasia due to TAM during adjuvant therapy after surgery occurred, and atypical endometrial hyperplasia developed even after discontinuation of this drug. (Poster Session Venue | Kyoto International Conference Center, 1st Floor Event Hall, New Hall; In-Person) - Jun 26, 2026 - Abstract #JBCS2026JBCS_1857;
Postoperative adjuvant therapy was planned with leuprorelin (2 years) + TAM (5 years) with the aim of suppressing ovarian function due to the patient's young age...When it is classified as "atypical," it is assumed that a gene mutation has occurred, and the possibility of developing endometrial cancer increases, so surgery is considered. At the general meeting, the treatment course at Gyne will be added, along with a literature review, to the report.

|||||||||| Verzenio (abemaciclib) / Eli Lilly
A case of metastatic or recurrent breast cancer in which the patient gave birth due to a strong desire to continue the pregnancy. (Poster Session Venue | Kyoto International Conference Center, 1st Floor Event Hall, New Hall; In-Person) - Jun 26, 2026 - Abstract #JBCS2026JBCS_1841;
[Conclusion] This report describes a case in which the patient struggled to balance breast cancer treatment and fertility preservation. Thanks to the efforts of multidisciplinary professionals at a higher-level medical institution, the patient was able to continue the pregnancy and give birth despite the metastatic and recurrent breast cancer, and the child had a good outcome and the mother's condition stabilized.

|||||||||| Herceptin (trastuzumab) / Roche
Practical Aspects of Breast Cancer Treatment During Pregnancy: Experiences from Two Cases (Poster Session Venue | Kyoto International Conference Center, 1st Floor Event Hall, New Hall; In-Person) - Jun 26, 2026 - Abstract #JBCS2026JBCS_977;
After giving colostrum, she was weaned, and two weeks postpartum, she started treatment with paclitaxel (PTX) + trastuzumab, and after completion, she started endocrine therapy (tamoxifen + leuprorelin)...From 20 weeks of pregnancy, she received EC therapy (epirubicin + cyclophosphamide) for 4 courses, and had a planned delivery at 37 weeks of pregnancy...After 4 weekly PTX treatments, she developed febrile neutropenia, so thereafter she received 3 docetaxel treatments in combination with G-CSF, followed by postoperative radiotherapy (PMRT) after total mastectomy...Furthermore, at our hospital, we collaborate across departmental and professional boundaries to address the needs of AYA patients, holding regular meetings to discuss various types of cancer affecting the AYA generation. [Conclusion] In cases of breast cancer during pregnancy, it is crucial for a multidisciplinary team to consider the optimal treatment method for each case, taking into account the subtype, stage, and gestational age.

|||||||||| Enhertu (fam-trastuzumab deruxtecan-nxki) / Daiichi Sankyo, AstraZeneca
A case of Luminar A breast cancer that showed negative sentinel lymph node metastasis, recurred in the axilla 3 months later, and followed a rapid course of the disease. (Poster Session Venue | Kyoto International Conference Center, 1st Floor Event Hall, New Hall; In-Person) - Jun 26, 2026 - Abstract #JBCS2026JBCS_616;
Low HER2 levels were confirmed, and she received one dose of T-DXd, but she died 2 years and 6 months after the initial surgery. It is possible that her rapid progression was due to low HER2 levels, even though it was Luminar A breast cancer.

|||||||||| letrozole / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., indomethacin / Generic mfg.
Hypercalcemia as A Result of Uterine Leiomyomas: A Case Report (ENDOExpo; Poster Floor) - Jun 2, 2026 - Abstract #ENDO2026ENDO_3813;
This case emphasizes that benign gynecological conditions should be considered in the differential diagnosis of hypercalcemia in the absence of an identifiable malignancy. In conclusion, Leiomyomatosis is a rare cause of PTH-rP mediated hypercalcemia and can resolve entirely following surgical resection.

|||||||||| abiraterone acetate / Generic mfg.
Disrupted Adrenal Steroidogenesis with Abiraterone Therapy: Concurrent Mineralocorticoid Excess and Adrenal Insufficiency (AI) (ENDOExpo; Poster Floor) - Jun 2, 2026 - Abstract #ENDO2026ENDO_3573;
It blocks 17-alpha hydroxylation of pregnenolone and progesterone which precede cortisol and androgen synthesis...Case: An 86-year-old man with metastatic prostate cancer, status post radical prostatectomy on leuprolide, abiraterone, and prednisone presented with acute encephalopathy...Empiric antibiotics, acyclovir and Dexamethasone were started...Dexamethasone was stopped; stress doses of hydrocortisone were started and eventually converted to maintenance prednisone therapy for presumed primary AI due to CYP17A1 inhibitor use...Hypertension and hypokalemia were successfully treated with spironolactone, a mineralocorticoid receptor antagonist... Our case highlights the consequences of Abiraterone therapy in the absence of a long-acting GC; the need for patient education, and recommendations for appropriate management.

|||||||||| leuprolide acetate for depot suspension / Generic mfg.
Efficacy and Safety of 3-Month Leuprorelin Acetate Microspheres in Chinese Children with Central Precocious Puberty: A Prospective Multicenter Study (ENDOExpo; Poster Floor) - Jun 2, 2026 - Abstract #ENDO2026ENDO_3369;
Our case highlights the consequences of Abiraterone therapy in the absence of a long-acting GC; the need for patient education, and recommendations for appropriate management. The 3-month leuprorelin acetate microsphere formulation effectively suppressed the pituitary-gonadal axis and slowed pubertal progression in children with CPP, with a tolerable safety profile.

|||||||||| leuprolide acetate for depot suspension / Generic mfg.
Short-Term Hemodynamic Profile in Girls with Idiopathic Central Precocious Puberty under Gonadotropin-Releasing Hormone Agonist Therapy: Integrated Evaluation with ABPM, Central Hemodynamics, and Carotid Strain (ENDOExpo; Poster Floor) - Jun 2, 2026 - Abstract #ENDO2026ENDO_3368;
Methods This prospective study included 25 girls with ICPP evaluated before treatment initiation and after 3 and 6 months of depot leuprolide acetate therapy...Instead, baseline adiposity appeared to account for much of the interindividual variability in hemodynamic measures. These findings support the short-term cardiovascular safety of GnRHa therapy and emphasize the importance of evaluating weight status at the time of treatment initiation.

|||||||||| leuprolide acetate for depot suspension / Generic mfg.
Can Exogenous Testosterone Exposure Trigger Persistent Premature Pubarche ? (ENDOExpo; Poster Floor) - Jun 2, 2026 - Abstract #ENDO2026ENDO_3364;
A leuprolide stimulation test done did not show central precocious puberty...To our knowledge, there are no current publications that have found a relationship between exogenous testosterone exposure and early pubarche which has persisted after removal of exposure. In our opinion, for patients with premature pubarche due to exogenous testosterone exposure, long term follow up is necessary.

|||||||||| leuprolide acetate for depot suspension / Generic mfg., triptorelin / Generic mfg.
Patient Characteristics, Treatment Patterns, and Resource Usage in Children Diagnosed with Central Precocious Puberty in China: A Real-World Retrospective Study (ENDOExpo; Poster Floor) - Jun 2, 2026 - Abstract #ENDO2026ENDO_3316;
In our opinion, for patients with premature pubarche due to exogenous testosterone exposure, long term follow up is necessary. Among the FAS population (n=1,477; 94.7% female; mean age, 8.43

|||||||||| leuprolide acetate for depot suspension / Generic mfg.
Late-Presenting 46,XY Disorder of Sex Development Due to 17?-Hydroxysteroid Dehydrogenase Type 3 Deficiency with Complex Endocrine and Psychosocial Outcomes. (ENDOExpo; Poster Floor) - Jun 2, 2026 - Abstract #ENDO2026ENDO_3311;
Emphasizing the importance of early diagnosis, structured transition, and guideline-aligned longitudinal multidisciplinary care. Reference: Hughes IA, et al.

|||||||||| Prolia (denosumab) / Amgen
Are Men with Prostate Cancer Treated with Androgen Deprivation Therapy Being Appropriately Screened for Bone Loss? (ENDOExpo; Poster Floor) - Jun 2, 2026 - Abstract #ENDO2026ENDO_2927;
ASCO recommends treatment with an osteoclast inhibitor, either denosumab or bisphosphonate, if patients meet a clinical diagnosis of osteoporosis, or a T-score -2.5 and a FRAX score 10-year probability of a major osteoporotic fracture >20% or hip fracture >3%...Methods We conducted a retrospective chart review of 850 patients with ICD-10 code C61 (prostate cancer) and NDC code for leuprolide, 0074-3642-03, that were seen in the primary care, endocrinology, oncology, or urology clinics in our hospital system July 2020-July 2025...Unlike previous studies, our study did not show a reduction in fracture rates in those receiving baseline DXA scan. Further education for those that treat men with prostate cancer after ADT is needed to improve screening rates and treatment of osteoporosis in these patients.

|||||||||| An Unexpected Thyroid Detour in Reproductive Care (ENDOExpo; Poster Floor) - Jun 2, 2026 - Abstract #ENDO2026ENDO_2575;
Case A 37-year-old woman with a history of infertility and uterine leiomyoma presented with two weeks of worsening anterior neck pain and swelling associated with odynophagia, with symptoms unresponsive to acetaminophen and naproxen...She was treated with propranolol 10 mg TID and a 7-day prednisone taper, with advice to defer further infertility treatment until euthyroidism was achieved...It highlights leuprolide-induced thyroiditis as an underrecognized complication of GnRH agonist therapy, particularly in patients undergoing fertility treatment, where thyroid dysfunction may affect reproductive outcomes. Clinicians should maintain a high index of suspicion for thyroid dysfunction after leuprolide exposure, and baseline thyroid evaluation with close biochemical monitoring may facilitate early recognition and management.

|||||||||| Orgovyx (relugolix) / Takeda, Sumitomo Pharma, Pfizer
A Case of Leydig Cell Tumor Causing Persistent Hyperandrogenism in a Patient on Androgen Deprivation Therapy (ENDOExpo; Poster Floor) - Jun 2, 2026 - Abstract #ENDO2026ENDO_2541;
Clinicians should maintain a high index of suspicion for thyroid dysfunction after leuprolide exposure, and baseline thyroid evaluation with close biochemical monitoring may facilitate early recognition and management. He was started on leuprolide, abiraterone, and underwent radiation therapy...During the second year of treatment, PSA rose to 1.24 ng/mL with testosterone reported up to 700-800 ng/dL range (250

|||||||||| leuprolide acetate for depot suspension / Generic mfg., zoledronic acid / Generic mfg.
Monostotic Fibrous Dysplasia of Skull (ENDOExpo; Poster Floor) - Jun 2, 2026 - Abstract #ENDO2026ENDO_1803;
Prostate biopsy confirmed high grade Gleason 8 prostate cancer which was treated with radiation and leuprolide...Vitamin D supplementation and therapy with zoledronic acid for pain are planned...Treatment of craniofacial FD(CFFD) needs multidisciplinary approach with goals to prevent function loss (hearing or vision impairment), reducing facial deformity and long-term morbidity. Any active disease with rapid growth, new pain, functional loss warrants surgical referral.

|||||||||| Perjeta (pertuzumab) / Roche
Transient Thyroid Index Abnormalities in a Patient Taking Biotin: Signal or Laboratory Noise ? (ENDOExpo; Poster Floor) - Jun 2, 2026 - Abstract #ENDO2026ENDO_1342;
Patient remained on ovarian suppression with leuprolide and an aromatase inhibitor...Isolated TSH suppression on Roche-based assays should be interpreted cautiously when other thyroid indices remain normal, especially in a patient with normal renal function. Points to be discussed

|||||||||| leuprolide acetate for depot suspension / Generic mfg.
A Cautionary Case of PIT-1 Lineage Pituitary Adenoma with Rapid Regrowth (ENDOExpo; Poster Floor) - Jun 2, 2026 - Abstract #ENDO2026ENDO_1111;
Rapid postoperative regrowth underscores the importance of close radiographic surveillance, timely visual field assessment, and early multidisciplinary management. It also raises consideration for earlier adjuvant therapy in select PIT-1 adenomas exhibiting invasive or proliferative characteristics.

||||||||||  GVV858 / Novartis
Enrollment change:  CGVV858A12101: Study of GVV858 as a single agent or in combination with endocrine therapy in patients with HR+/HER2- breast cancer and other advanced solid tumors (EUDRACT) -  May 17, 2026
P1/2, N=55, Not yet recruiting,  Sponsor: Novartis Pharma AG
It also raises consideration for earlier adjuvant therapy in select PIT-1 adenomas exhibiting invasive or proliferative characteristics. N=26 --> 55

|||||||||| terazosin / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
Clinical, Journal: Terazosin as a Non-Hormonal Treatment for Endometriosis. (Pubmed Central) - May 13, 2026
NF-?B decreased in tissue and serum (p < 0.001) but not in peritoneal fluid (p = 0.206). Overall, terazosin produced leuprolide-like molecular benefits without hormonal suppression, supporting repurposing as a candidate non-hormonal therapy, while highlighting the need for longer-duration studies and randomized clinical trials given model and pain-assessment limitations.

|||||||||| leuprolide acetate for depot suspension / Generic mfg.
Efficacy and Safety of 3-Month Leuprorelin Acetate Microspheres in Chinese Children with Central Precocious Puberty: A Prospective Multicenter Study (Room W187) - May 11, 2026 - Abstract #ENDO2026ENDO_920;
Overall, terazosin produced leuprolide-like molecular benefits without hormonal suppression, supporting repurposing as a candidate non-hormonal therapy, while highlighting the need for longer-duration studies and randomized clinical trials given model and pain-assessment limitations. The 3-month leuprorelin acetate microsphere formulation effectively suppressed the pituitary-gonadal axis and slowed pubertal progression in children with CPP, with a tolerable safety profile.

|||||||||| leuprolide acetate for depot suspension / Generic mfg., medroxyprogesterone injection / Generic mfg.
Journal: Success of menstrual suppression for patients with obstructive Mullerian anomalies. (Pubmed Central) - May 11, 2026
Many patients reported effective suppression with COC pills containing 30 mcg of EE. Almost half of the patients reported poor pain control with the initial menstrual suppression method.

|||||||||| leuprolide acetate for depot suspension / Generic mfg.
Journal: Microfluidic Engineering of Core-Shell PLGA Microspheres with Adjustable Shell Thickness for Long-Acting Delivery of Leuprolide Acetate. (Pubmed Central) - May 5, 2026
Under the appropriate thickness, the LA concentration could also function to improve the encapsulation properties. Overall, this work provides mechanistic insight into the structure-performance relationship of microfluidic manipulated core-shell PLGA microspheres for long-term release of LA and establishes a rational foundation for the design of predictable long-acting peptide delivery systems.

||||||||||  leuprolide acetate for depot suspension / Generic mfg.
Trial completion date, Trial primary completion date:  Comparison of the Therapeutic Effects of Vaginal Repair With Leuprorelin and Vaginal Repair in the Treatment of Cesarean Section Scar Defect (clinicaltrials.gov) -  Apr 24, 2026
P=N/A, N=94, Recruiting,  Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Overall, this work provides mechanistic insight into the structure-performance relationship of microfluidic manipulated core-shell PLGA microspheres for long-term release of LA and establishes a rational foundation for the design of predictable long-acting peptide delivery systems. Trial completion date: Apr 2026 --> Dec 2027 | Trial primary completion date: Apr 2025 --> Apr 2027

||||||||||  Etcamah (camizestrant) / AstraZeneca
Trial completion date, Circulating tumor DNA:  Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (clinicaltrials.gov) -  Apr 21, 2026
P3, N=315, Active, not recruiting,  Sponsor: AstraZeneca
Trial completion date: Apr 2026 --> Dec 2027 | Trial primary completion date: Apr 2025 --> Apr 2027 Trial completion date: Nov 2027 --> Sep 2028

|||||||||| Nubeqa (darolutamide) / Bayer, Orion Corp
A phase 2 study of darolutamide plus leuprolide acetate in hormone therapy (E450b) - Apr 21, 2026 - Abstract #ASCO2026ASCO_2941;
P2
Trial completion date: Nov 2027 --> Sep 2028 Funded by U.S. National Institutes of Health Bayer Clinical Trial Registration Number: NCT05669664 The full, final text of this abstract will be available on May 21 at 05:00 PM EST.

|||||||||| leuprolide acetate for depot suspension / Generic mfg.
Journal: Comparative Study of Subcutaneous 6-Month Versus Intramuscular 3-Month Leuprorelin Use in Central Precocious Puberty. (Pubmed Central) - Apr 19, 2026
Only 6-month subcutaneous leuprorelin could reduce uterine and breast volumes. Pain was more prominent with six-month subcutaneous leuprorelin, and drug deposition in the subcutaneous tissue was identified more frequently, without an inflammatory process or a risk of therapeutic failure.

|||||||||| leuprolide acetate for depot suspension / Generic mfg., Orgovyx (relugolix) / Takeda, Sumitomo Pharma, Pfizer
Journal: Relugolix : the first oral GnRH receptor antagonist for the treatment of advanced hormone-sensitive prostate cancer (Pubmed Central) - Apr 16, 2026
The treatment was generally well tolerated, with mostly grade 1 or 2 adverse events. Its oral formulation, once-daily dosing, and rapid reversibility position relugolix as a promising therapeutic option, especially in individualized treatment strategies.

||||||||||  Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Enrollment closed, Trial primary completion date:  ADEPT: A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (clinicaltrials.gov) -  Apr 2, 2026
P2, N=393, Active, not recruiting,  Sponsor: Dana-Farber Cancer Institute
Its oral formulation, once-daily dosing, and rapid reversibility position relugolix as a promising therapeutic option, especially in individualized treatment strategies. Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2026 --> Mar 2026

|||||||||| Trial primary completion date: Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing (clinicaltrials.gov) - Apr 2, 2026
P2, N=39, Recruiting, Sponsor: Peking Union Medical College
Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2026 --> Mar 2026 Trial primary completion date: Jul 2026 --> Jul 2028

|||||||||| goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., triptorelin / Generic mfg.
Incidence of Early Ovarian Suppression Failure in Premenopausal Breast Cancer Patients at an Academic Medical Center (Exhibit Hall I2) - Mar 28, 2026 - Abstract #HOPA2026HOPA_251;
Patients were included if they had received leuprolide, triptorelin, and/or goserelin and had an estradiol level drawn between January 2024 and October 2025. In progress In progress

|||||||||| Network-based discovery of tumor-checkpoint inverter drugs targeting pancreatic ductal adenocarcinoma cell states and macrophage reprogramming (Section 16) - Mar 17, 2026 - Abstract #AACR2026AACR_5807;
Predicted MR-inversion scores correlated with experimental dose-response profiles in cell lines selected via OncoMatch.Together, these results establish a mechanistic link between tumor-intrinsic transcriptional states and macrophage immunosuppression, while identifying mutation-agnostic, state-specific drugs capable of reprogramming both tumor and immune compartments. This work provides a generalizable framework for network-based drug repurposing to overcome transcriptional plasticity and immune resistance in PDAC.

|||||||||| leuprolide acetate for depot suspension / Generic mfg., leuprolide acetate injection / Generic mfg.
Journal: Sterile abscess following intramuscular leuprolide acetate injection for endometriosis: A case report. (Pubmed Central) - Mar 13, 2026
LA is a common treatment for refractory endometriosis in pediatric patients, but providers may be unaware of the risk of sterile abscess. We did not identify any predictive or preventative factors but propose that prior treatment may have increased risk in this case.

|||||||||| leuprolide acetate for depot suspension / Generic mfg.
PK/PD data, Journal: Fixed Dosing of Leuprolide Acetate, a GnRH Agonist, in Children with Central Precocious Puberty: A Population Pharmacokinetic Justification. (Pubmed Central) - Mar 13, 2026
P3
The developed model adequately characterized leuprolide pharmacokinetics in pediatrics. No significant covariate effects were observed, supporting the use of a fixed leuprolide dose in pediatrics.

|||||||||| Firmagon (degarelix) / Astellas, Ferring
Cardiovascular Consequences of Androgen Deprivation Therapy in Prostate Cancer Patients: A Short-Term Prospective Analysis (206) - Mar 13, 2026 - Abstract #AUA2026AUA_3652;
No significant covariate effects were observed, supporting the use of a fixed leuprolide dose in pediatrics. Sixty prostate cancer patients (mean age 68.1

|||||||||| Xtandi (enzalutamide) / Pfizer, Astellas
Duration of treatment suspension among all randomized patients in EMBARK (206) - Mar 13, 2026 - Abstract #AUA2026AUA_3647;
P3
Despite nearly 6 months longer tx suspension, enza combo demonstrated superior OS compared with leuprolide alone. This finding supports the potential for intermittent tx with enza combo to maintain efficacy while reducing tx burden in pts with hrBCR prostate cancer.

|||||||||| Xtandi (enzalutamide) / Pfizer, Astellas
Comparison of EMBARK and EAU Criteria to Identify High-Risk Patients with Biochemical Recurrence After Radical Prostatectomy (146A) - Mar 13, 2026 - Abstract #AUA2026AUA_2343;
e. PSADT 9-12 months or grade group 4-5 without EMBARK criteria), outcomes are similar to EAU low-risk disease.

|||||||||| Prolia (denosumab) / Amgen
Association Between LHRH Agonist Therapy and Urinary Stone Disease in Men with Prostate Cancer: A Live Database Analysis (147B) - Mar 13, 2026 - Abstract #AUA2026AUA_1288;
The risk attenuation observed with concomitant bisphosphonate or denosumab use suggests that preservation of bone mineral balance may mitigate ADT-related lithogenic changes. These findings highlight a potential lithogenic consequence of ADT and raise the possibility that antiresorptive therapy may confer protective effects against nephrolithiasis in this population.

|||||||||| Xtandi (enzalutamide) / Pfizer, Astellas, leuprolide acetate for depot suspension / Generic mfg.
Journal, Monotherapy: Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary Endpoints. (Pubmed Central) - Mar 9, 2026
P3
Secondary endpoint results support enzalutamide monotherapy as a potential option to improve efficacy and preserve sexual health vs leuprolide alone for patients with high-risk biochemical recurrence. NCT02319837.

|||||||||| goserelin acetate / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
PHARMACOECONOMIC EVALUATION OF DIFFERENT GONADOTROPIN-RELEASING HORMONE ANALOGS IN THE TREATMENT OF PREMENOPAUSAL HORMONE RECEPTOR-POSITIVE BREAST CANCER IN CHINA () - Mar 6, 2026 - Abstract #ISPOR2026ISPOR_1134;
NCT02319837. Leuprorelin-3M demonstrates economic advantages over leuprorelin 1M and goserelin 1M by reducing the number of injections and lowering costs, benefiting multiple stakeholders including healthcare providers, patients and payers.

|||||||||| leuprolide acetate for depot suspension / Generic mfg., triptorelin / Generic mfg.
PHARMACOECONOMIC EVALUATION OF DIFFERENT GONADOTROPIN-RELEASING HORMONE ANALOGS IN THE TREATMENT OF CHILDREN WITH CENTRAL PRECOCIOUS PUBERTY IN CHINA () - Mar 6, 2026 - Abstract #ISPOR2026ISPOR_760;
Leuprorelin-3M demonstrates economic advantages over leuprorelin 1M and goserelin 1M by reducing the number of injections and lowering costs, benefiting multiple stakeholders including healthcare providers, patients and payers. Leuprorelin-3M has economic advantages over leuprorelin-1M and triptorelin-1M by reducing the number of hospital visits and lowering treatment costs, benefiting multiple parties including healthcare providers, patients and payers.

|||||||||| Two Roads to Shock: A Mediastinal Mass With Dual Hemodynamic Impact (Area G, Halls WA2-WA3 (Level II, OCCC West Concourse); Poster Board # P1257) - Mar 3, 2026 - Abstract #ATS2026ATS_7337;
Pre-phase treatment was started with bortezomib and prednisone followed by daunorubicin and bortezomib per the AALL1231 protocol...Extrinsic compression of the pulmonary artery causing RV failure, elevated pulmonary artery pressure, and normal wedge define group IV pulmonary hypertension, which this patient developed. Treatment would be best aimed at relieving the obstruction through surgical interventions or chemo/radiation therapy.

|||||||||| leuprolide acetate for depot suspension / Generic mfg.
Recurrent Massive Bilateral Catamenial Hemothoraces With Buffalo Chest Syndrome (Area D, Halls WA2-WA3 (Level II, OCCC West Concourse); Poster Board # P613) - Mar 3, 2026 - Abstract #ATS2026ATS_6663;
She has previously failed Depo-Lupron and combined hormonal contraceptives...TES remains diagnostically and therapeutically challenging due to its rarity, underrecognized menstrual correlation, and high recurrence rates despite surgery. This underscores the importance of clinical awareness and multidisciplinary collaboration in ensuring timely diagnosis and optimizing outcomes in these patients.

|||||||||| leuprolide acetate for depot suspension / Generic mfg.
Refractory Catamenial Pneumothorax Demonstrating Diagnostic and Therapeutic Challenges (Area D, Halls WA2-WA3 (Level II, OCCC West Concourse); Poster Board # P608) - Mar 3, 2026 - Abstract #ATS2026ATS_6658;
Despite initiation of leuprolide for prevention, she recently developed a recurrent pneumothorax with tension physiology, requiring repeat VATS with total pleurectomy and redo-pleurodesis...Despite repeated surgical intervention and hormonal suppressive therapy, our patient continued to have recurrent pneumothoraces. In refractory cases such as this, surgically-induced menopause with hysterectomy and bilateral salpingo-oophorectomy has been used with mixed success, emphasizing the need for further study in this population.

|||||||||| letrozole / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
A Rare Case of Pneumonitis Associated With Leuprolide and Letrozole Therapy for Breast Cancer (Area B, Halls WA2-WA3 (Level II, OCCC West Concourse); Poster Board # P234) - Mar 3, 2026 - Abstract #ATS2026ATS_2014;
While in two cases, the causative effect of leuprolide on pneumonitis is obscured by other concomitant medications, three other cases suggest both letrozole and leuprolide play direct roles through an unknown etiology. We report a case of delayed onset letrozole and leuprolide induced pneumonitis that responded well to high dose corticosteroid therapy.

|||||||||| prednisone / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
Nicolau Syndrome in a Child: A Rare Injection-Related Complication (Colorado Convention Center (Lobby C, Poster Center 1)) - Mar 2, 2026 - Abstract #AAD2026AAD_2276;
We present a pediatric case of NS following IM leuprolide...He was treated with antihistamines, NSAIDs, and a prednisone injection...Although etiology remains unclear, NS is considered an unpredictable complication independent of number of injections or medication type, dose, or injection frequency, and recurrence is not expected. This case adds to limited pediatric literature, highlights diagnostic challenges, and supports continued IM injection use when clinically indicated.

|||||||||| Journal: Undifferentiated Castration-Resistant Prostate Cancer Successfully Treated With Carboplatin and Paclitaxel. (Pubmed Central) - Mar 2, 2026
After 73 cycles, chemotherapy was discontinued, and the patient has remained in remission during follow-up. This case highlights the potential efficacy of carboplatin and paclitaxel in treating poorly differentiated CRPC, suggesting the need for further investigation into platinum-based regimens for aggressive prostate cancer variants.

|||||||||| Orgovyx (relugolix) / Takeda, Sumitomo Pharma, Pfizer
Withdrawal of presentation - Toward Safer Androgen Deprivation: A MetaAnalysis of Relugolix Versus GnRH Agonists in Prostate Cancer with Radiotherapy (Poster venue | Pacifico Yokohama Exhibition Hall D) - Mar 2, 2026 - Abstract #JSMO2026JSMO_2162;
These findings support Relugolix as a preferable ADT option, especially for those with cardiovascular risk. Further randomized trials are needed to confirm long term benefits.

|||||||||| leuprolide acetate for depot suspension / Generic mfg., tamoxifen / Generic mfg.
Withdrawal of presentation - Efficacy and Safety of Leuprolide Plus Tamoxifen Versus Tamoxifen in Premenopausal HR+ Breast Cancer (Poster venue | Pacifico Yokohama Exhibition Hall D) - Mar 2, 2026 - Abstract #JSMO2026JSMO_1761;
Extending leuprolide beyond 2 years offers no clear benefit except in selected higher-risk patients. Optimal treatment duration should balance oncologic benefit with long-term quality of life.



	Diseases Companies Products Productz Mechanisms of Action Sites